Relay Therapeutics Advances Zovegalisib in Breast Cancer and Vascular Anomalies — Relay Therapeutics, Inc.

Event summary

Relay Therapeutics selected zovegalisib plus atirmociclib as the go-forward triplet regimen for first-line (1L) breast cancer, with a Phase 3 trial expected to initiate in early 2027.
Initial positive clinical data from the Phase 1/2 ReInspire trial in vascular anomalies was presented at the ISSVA World Congress 2026.
The company reported approximately $911 million in cash, cash equivalents, and investments as of Q2 2026.
Relay Therapeutics raised approximately $316 million in a follow-on public offering in May 2026.

The big picture

Relay Therapeutics is advancing its lead program, zovegalisib, through multiple clinical trials aimed at addressing significant patient populations in breast cancer and vascular anomalies. The company's strategic focus on mutant-selective PI3Kα inhibition positions it within the broader trend of precision medicine, aiming to overcome limitations of traditional PI3Kα inhibitors. With a strong cash position and ongoing clinical execution, Relay Therapeutics is poised to capitalize on potential regulatory and commercial milestones in the coming years.

What we're watching

Clinical Progress: The initiation of the Phase 3 trial in first-line breast cancer and the presentation of initial clinical data for zovegalisib in vascular anomalies will be key milestones to monitor.
Regulatory Feedback: The timing and outcome of regulatory feedback for the planned Phase 3 trial in endocrine-sensitive breast cancer will impact the company's development strategy.
Financial Runway: The company's strong cash position with expected runway into 2029 provides a buffer, but the pace of clinical and regulatory milestones will determine its long-term financial health.